TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
NextCell Pharma AB
Closing information (x1000 EUR)
Closing information | 2023/08 | 2022/08 | 2021/08 |
Turnover |
854
|
523
|
385 |
Financial expenses |
0
|
1
![]() |
1 |
Earnings before taxes |
-3,362
|
-3,235
|
0 |
EBITDA |
-3,424
|
-3,236
|
43 |
Total assets |
7,500
|
11,669
|
15,318 |
Current assets |
5,680
|
9,994
|
14,417 |
Current liabilities |
851
|
649
|
389 |
Equity capital |
6,394
|
10,816
|
14,773 |
- share capital |
595
|
660
|
694 |
Employees (average) |
17
|
15
|
13 |
Financial ratios
Fiscal year | 2023/08 | 2022/08 | 2021/08 |
Solvency |
85.3%
|
92.7%
|
96.4% |
Turnover per employee |
50
|
35
|
30 |
Profit as a percentage of turnover |
-393.7%
|
-618.5%
|
0% |
Return on assets (ROA) |
-44.8%
|
-27.7%
|
0.0% |
Current ratio |
667.5%
|
1539.9%
|
3706.2% |
Return on equity (ROE) |
-52.6%
|
-29.9%
|
0% |
Change turnover |
382
|
157
|
34 |
Change turnover % |
81%
|
43%
|
10% |
Chg. No. of employees |
2
![]() |
2
|
3 |
Chg. No. of employees % |
13%
|
15%
|
30% |
Total value of public sale
Fiscal year | 2023/08 | 2022/08 | 2021/08 |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.